Mr. Bruce is the Regional President, North America for the Rare Disease Business at Pfizer, Inc.  In this role, he is responsible for the Rare Disease portfolio in the US and Canada, including oversight of key brands such as Vyndaqel/Vyndamax and Pfizer Rare Disease’s gene therapy pipeline.

Prior to this, Bert served as the Vice President, Global Commercial Development, Rare Disease, where he led work with teams spanning the breadth of the drug development cycle – from early stage compounds through late-stage commercial development, including business development to acquire new medicines and launch readiness for the pipeline portfolio. With over 30 years of broad pharmaceutical experience, he has held diverse leadership positions across Marketing, Sales, Finance and Market Research, with scopes both Global and regional.

Bert began his career with Johnson & Johnson, where he led brands and teams in the therapeutic areas of neuroscience, mycology, allergy and gastrointestinal disease. He joined Pfizer from Wyeth, where he was accountable for global strategy and performance for the neuroscience portfolio in Latin America, Asia-Pacific and Canada.

As the chair of the Pfizer Global Black Community, Bert has played a leading role in helping Pfizer respond to issues of racial inequities and was instrumental in the development of Biopharma’s Equity Commitments. He is on the President’s Leadership Council at Thomas Jefferson University and Jefferson Health, and is a board member for Bold Hope, Inc.

Bert holds a B.S. from Eastern University and an MBA from the Wharton School of Business (University of Pennsylvania). He lives in Doylestown, PA with his wife, Kathleen and has three children. He is an active member at Keystone Fellowship in Montgomeryville, PA, and in his free time, enjoys spending time outdoors, watching or playing sports of any kind, and listening to live music of various genres.